製品の概要

製品の詳細

  • 由来Recombinant
  • 由来Escherichia coli
  • アミノ酸配列
    • 生物種Human
    • 配列MDVTIQHPWF KRTLGPFYPS RLFDQFFGEG LFEYDLLPFL SSTISPYYRQ SLFRTVLDSG ISEVRSDRDK FVIFLDVKHF SPEDLTVKVQ DDFVEIHGKH NERQDDHGYI SREFHRRYRL PSNVDQSALS CSLSADGMLT FCGPKIQTGL DATHAERAIP VSREEKPTSA PSS
    • 領域1 to 173

特性

Our Abpromise guarantee covers the use of ab48778 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • アプリケーション

    Functional Studies

    SDS-PAGE

    Western blot

  • 精製度> 95 % SDS-PAGE.

  • 製品の状態Liquid
  • Concentration information loading...

前処理および保存

  • 保存方法および安定性

    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

    Preservative: None
    Constituents: 50mM Sodium chloride, 20mM Tris HCl, 1mM EDTA, pH 7.5

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

関連情報

  • 別名
    • Acry 1
    • Alpha crystallin A chain
    • Alpha-crystallin A chain
    • CRYA 1
    • CRYA1
    • CRYAA
    • CRYAA_HUMAN
    • Crystallin alpha 1
    • Crystallin alpha A
    • Heat shock protein beta 4
    • Heat shock protein beta-4
    • HSPB 4
    • HspB4
    • short form
    • Zonular Central Nuclear Cataract
    see all
  • 機能May contribute to the transparency and refractive index of the lens.
  • 関連疾患Defects in CRYAA are a cause of cataract autosomal dominant (ADC) [MIM:604219]. Cataract is an opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. Cataract is the most common treatable cause of visual disability in childhood.
  • 配列類似性Belongs to the small heat shock protein (HSP20) family.
  • 翻訳後修飾O-glycosylated; contains N-acetylglucosamine side chains.
    Deamidation of Asn-101 in lens occurs mostly during the first 30 years of age, followed by a small additional amount of deamidation (approximately 5%) during the next approximately 38 years, resulting in a maximum of approximately 50% deamidation during the lifetime of the individual.
    Phosphorylation on Ser-122 seems to be developmentally regulated. Absent in the first months of life, it appears during the first 12 years of human lifetime. The relative amount of phosphorylated form versus unphosphorylated form does not change over the lifetime of the individual.
  • 細胞内局在Cytoplasm. Nucleus. Translocates to the nucleus during heat shock and resides in sub-nuclear structures known as SC35 speckles or nuclear splicing speckles.
  • Information by UniProt

Recombinant human alpha A Crystallin protein 画像

  • 14% SDS-PAGE gel loaded with ab48778,
    recombinant human alpha A Crystallin protein,
    predicted molecular weight 19.9 kDa
  • Anti-alpha A Crystallin antibody [1H3.B8] (ab78439) at 1 µg/ml + Recombinant human alpha A Crystallin protein (ab48778) at 0.1 µg

    Secondary
    Goat Anti-Mouse IgG H&L (HRP) preadsorbed (ab97040) at 1/5000 dilution
    Developed using the ECL technique

    Performed under reducing conditions.

    Exposure time : 16 minutes

Recombinant human alpha A Crystallin protein (ab48778) 使用論文

This product has been referenced in:
  • Fan Q  et al. Identification of proteins that interact with alpha A-crystallin using a human proteome microarray. Mol Vis 20:117-24 (2014). Read more (PubMed: 24453475) »
  • Rao NA  et al. Small Heat Shock Protein aA-Crystallin Prevents Photoreceptor Degeneration in Experimental Autoimmune Uveitis. PLoS One 7:e33582 (2012). Read more (PubMed: 22479415) »

See all 2 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab48778.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"